| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e96496a9949403e2af2ca913e65bfec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bbdac88c2bd304b523b4ea0ea461bea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6815 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57 |
| filingDate |
2022-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb781ebb63df19ce5c022a556dc6b5e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eb492dd563f72ac10769a1a9b919be8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbe8fec79181baa105d29b1afb8a15b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_001365d52a18ba23a131c4a3bfbd1a17 |
| publicationDate |
2022-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022214108-A1 |
| titleOfInvention |
Recombinant fusion protease capable of eliminating in vivo immunoglobulin a, preparation method therefor, and application in treating iga nephropathy |
| abstract |
An AK183 protease-based recombinant fusion protein, and an application thereof in preparing a drug for IgA nephropathy and other related diseases mediated by IgA complex deposition. The recombinant fusion protein structure includes a human symbiotic bacteria protease AK183 active area and a human immunoglobulin fragment, the human immunoglobulin fragment being located at the N end of the protease AK183 active area. Also provided is a method for preparing the recombinant fusion protein. The recombinant fusion protein recombines and fuses the natural AK183 protease with the human immunoglobulin fragment, and has comprehensive advantages such as extended plasma half-life, effective removal of circulating and renal IgA complexes, and significant reduction of protease immunogenic side effects on the human body. The present invention is suitable for specifically treating IgA nephropathy and other related diseases mediated by IgA complex deposition. |
| priorityDate |
2021-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |